Go Deep
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -25,111 | -7.1 | -10.36 | -1.26 | 444.74 |
| Oct 2026 | -25,004 | -7.0 | -10.22 | -1.26 | 437.71 |
| Oct 2026 | -24,029 | -6.2 | -9.01 | -1.26 | 385.54 |
| Oct 2026 | -23,533 | -5.7 | -8.38 | -1.26 | 358.02 |
| Oct 2026 | -23,622 | -5.8 | -8.49 | -1.26 | 363.15 |
| Oct 2026 | -24,052 | -6.1 | -8.98 | -1.26 | 384.01 |
| Oct 2026 | -24,205 | -6.2 | -9.05 | -1.26 | 385.90 |
| Oct 2026 | -24,295 | -6.3 | -9.16 | -1.26 | 389.83 |
Aquestive Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 13,819,000.0 | 14,446,000.0 | 13,015,000.0 | 12,807,000.0 |
| Net Profit | -22,864,000.0 | -8,057,000.0 | -31,860,000.0 | -15,446,000.0 |
| EPS | -0.2 | -0.1 | -0.3 | -0.1 |
Aquestive Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 44,545,000.0 | 57,561,000.0 | 50,583,000.0 | 47,680,000.0 | — |
| Net Profit | -83,784,000.0 | -44,137,000.0 | -7,870,000.0 | -54,410,000.0 | — |
| EPS | -0.8 | -0.5 | -0.1 | -1.1 | — |
Aquestive Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 160,425,000.0 | 101,424,000.0 | 57,418,000.0 | 57,070,000.0 | — |
| Total Liabilities | 194,087,000.0 | 161,580,000.0 | 163,905,000.0 | 175,624,000.0 | — |
| Total Equity | -33,662,000.0 | -60,156,000.0 | -106,487,000.0 | -118,554,000.0 | — |
Owes vs Owns
Aquestive Therapeutics, Inc. owed $1.43 for every $1 it owned in Jun 2026, down from $3.08 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.43× | 1.21× | 1.59× | 2.85× | 3.08× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aquestive Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 75.5%Receivables 11.1%Inventory 3.8%Fixed assets (tangible) 5.3%Other assets 4.2%
How it's funded — Dec 2025
Short-term debt 5.1%Long-term debt 14.2%Payables 15.4%Other liabilities 65.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 121.2 | 71.5 | 23.9 | 27.3 |
| Receivables | 17.8 | 7.3 | 8.5 | 4.7 |
| Inventory | 6.2 | 6.0 | 6.8 | 5.8 |
| Fixed assets (tangible) | 8.5 | 9.0 | 9.7 | 9.3 |
| Intangible assets | 0.0 | 0.0 | 1.3 | 1.4 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.8 | 7.5 | 7.3 | 8.6 |
| Liabilities & equity | ||||
| Short-term debt | 10.0 | 0.0 | 0.0 | 18.7 |
| Long-term debt | 27.5 | 32.5 | 27.5 | 33.4 |
| Payables | 29.9 | 10.3 | 8.9 | 9.9 |
| Other liabilities | 126.7 | 118.8 | 127.4 | 113.5 |
| Shareholders' equity | -33.7 | -60.2 | -106.5 | -118.6 |
| Net tangible assets | -33.7 | -60.2 | -107.8 | -120.0 |
Aquestive Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -52,432,000.0 | -35,759,000.0 | -6,380,000.0 | -9,819,000.0 | — |
| Investing Activities | -562,000.0 | -159,000.0 | -995,000.0 | -2,524,000.0 | — |
| Financing Activities | 102,617,000.0 | 83,592,000.0 | 3,974,000.0 | 11,592,000.0 | — |